I have a flow system

Chapter 231 Pfizer's Attention

The equipment of Wu Zhou Company had already produced related products before Dr. Zhang’s results came out. In early May, the first prototype had already been released.

After that, the application was submitted to the State Drug Administration normally.

Before Wu Zhou started to make efforts to speed up the approval, the leaders of the relevant departments contacted him proactively after seeing the detailed technical details.

Afterwards, it will be listed as a key examination and approval project, and will be given priority for examination and approval.
Of course, the relevant departments of the company are fully cooperating, providing sufficient materials and data, and actively communicating with the approval personnel.

As for the information, because of AI assistance, except for a few parts, most of them are read in one pass, and the efficiency is unexpectedly high.

But the follow-up still needs to go through several rounds of rigorous technical review and safety assessment.

This is the "purchase" of equipment for top hospitals like Liu Yang and Zhang Wei.

In fact, it is a prototype for actual testing and safety evaluation.

Relevant data will be compiled regularly, and the Food and Drug Administration is also very concerned about it.

At the beginning of June, after nearly a million data verifications, the approval by the Food and Drug Administration accelerated again.

On the other hand, this equipment of Aiying Group has also been noticed by some other departments of the country.

Due to the slow speed of nucleic acid detection and the error of detection accuracy, it is easy to miss a diagnosis. In order to avoid this problem, we can only focus on sealing.

Then there are occasional visits to society for one or two
Time-consuming, labor-intensive, and especially expensive.

Now the equipment of Aiying Medical needs accuracy, accuracy, convenience, and efficiency. One piece of equipment can outperform more than ten sets of PCR equipment.
In a hurry, the relevant departments directly ordered 1 devices and allocated them to some major provinces and cities with high population mobility before the product was approved for marketing.

On the other hand, Huaxia's approval is accelerated, and the same is true for foreign countries, such as breakthrough technology, special approval, accelerated approval, accelerated listing, etc.
The speed is not slower than that in China.

Moreover, the actual market demand abroad, at least at the moment, is much greater than that in China.

Because of this CRISPR nucleic acid detection equipment, Aiying Group has been popular during this period.

"Md, Wu Zhou is so lucky, why did he catch up with him?" Someone said angrily.

Envious, jealous.

Because the market demand at home and abroad is really huge, the market demand in the domestic market alone is at least hundreds of thousands of units, which is worth tens of billions.

Of course, in addition to this, there is another piece of news that sparked heated discussions again.

"Recently, an inactivated mask vaccine developed by Huaxia Aiying Biological Company has achieved encouraging results in phase 2 clinical trials. According to reports, the vaccine uses an inactivated mask virus as an antigen, which can induce human body to produce anti- Neutralizing antibodies to mask virus.

A total of 2 healthy volunteers were recruited for this Phase 2000 clinical trial, and they were randomly divided into two groups, 1000 of whom were vaccinated with the inactivated mask vaccine, and the other 1000 were vaccinated with a placebo.The test results showed that more than 95% of the volunteers vaccinated with the inactivated mask vaccine developed high levels of neutralizing antibody titers after vaccination, and none of the volunteers experienced serious adverse reactions.

It is worth noting that the inactivated mask vaccine is a traditional and mature vaccine technology, and its main advantage is that it can retain the natural virus structure and immunogenicity.The success of this trial proved that the inactivated mask vaccine has good efficacy and safety in preventing and controlling mask virus infection.

Scientists said that the next step will be to carry out a larger phase 3 clinical trial to further verify the safety and effectiveness of the vaccine in different populations, regions and mutant strains, and optimize its preparation process and quality standards to provide global defense against The mask virus provides new weapons. "

This report comes out.
A kind of people who eat melons are even more dumbfounded.

"Is Aiying Biology related to the mask virus?"

"Which company is Aiying Biological Company? Why have I never heard of it? Do they have formal qualifications and approvals?"

"Aiying Biotech and Aiying Medical are both subsidiaries of Aiying Group."

"Am I not mistaken? It's Aiying again, and it's all from Aiying Group? Does Huaxia have another Aiying biological company?"

"Don't say anything, just send me the stock code, I want all in."

"It's really great! The success of the inactivated mask vaccine has given us confidence in winning this battle against the "epidemic"! Thanks to Huaxia Aiying Biological Company and all the scientists involved in the research and development and testing!"

"Hehe, the whole thing is wandering around in old technology. This should be the reason why our technology has been lagging behind Europe and the United States. mrna vaccine is the future trend. We should keep up with the pace of the times and we should reflect."

"Why don't you reflect on yourself, you didn't get into Tsinghua University, you didn't make money, you didn't carry the banner of China's scientific research"

"Everything is rethinking. You know how to ask others to reflect, but have you reflected on yourself? What about inactivated vaccines? Why can't such a safe traditional vaccine route be used? It's because Europe and the United States use the MRNA vaccine route. Is that good? The mrna vaccine route has not yet launched a single product. This kind of vaccine that the whole people needs is tested with this technical vaccine that has not yet been verified for safety? Ha ha."

"This trial is only 2000 people, not large enough."

"Are you really stupid or fake stupid? 2000 people are still few? The second phase is the second phase of clinical trials, and there is still a third phase, which is large-scale."

"Mr. Wu, you can't make a lot of money like this. The capital market is king. Hurry up and go public."

"+1"

In the office of the CEO of Pfizer, Smith is currently browsing the industry news.

As a company manager, not only to know the internal situation of the company.

Swipe your finger as usual to watch the latest news information in the industry, but your finger suddenly stops.

Smith picked up the phone at hand and called Mike, the marketing manager. "Mike, come here right now!"

"Okay, boss. What's the matter?" Mike was surprised when he got the call.He is discussing the recent market situation with his colleagues in the office, and is preparing to formulate the marketing strategy for the next stage.

"Don't ask, come here quickly!" Jack Smith urged, and then hung up the phone.

Mike felt a twinge of unease and hurried out of the office. "Sorry guys, I have to go. The boss is looking for me," he said to his colleagues.

"What's the matter? Is everything okay?" The colleagues looked at him curiously.

"I don't know, he sounds very serious. I hope it's not bad news." Mike shook his head and said helplessly.

Mike walked to Smith's office door and knocked on the door. "Boss, here I come. Can I come in?"

"Come in, and close the door." Smith's voice was a little low, but his face was still serious.

Mike walked into the office "Boss, what's the matter? You look very upset."

"Look at this and tell me what you think." Smith didn't answer him, but just pointed to his computer, motioning for him to look at it himself.

Mike looked at his boss suspiciously, and then walked over. After a while, his face became serious, and after about 3 minutes, he showed surprise.

"Do you understand what this means for our company?" Smith frowned.

Mike pondered for a while before seriously saying: "This is indeed a trouble, how could their research and development progress be so fast, even if it is accelerated approval, it should be the end of the second phase of clinical trials in a few months, unless they are in the early stage. The research and development has been extremely smooth, or it has already started earlier."

"Maybe they have some secret partners or investors that we don't know about, or maybe they have some breakthrough technology or method that we haven't heard of." Mike frowned, wondering.

"We need to investigate these later. The most urgent thing is that their product has entered the third phase, which is several months faster than ours." Smith shook his head and said.

"Yes, according to the news, this vaccine is an inactivated vaccine. This is a traditional and mature technology. Compared with our company's current mRNA vaccine, it is easier to gain the trust and approval of the public and regulatory agencies. And the inactivated vaccine Live vaccines can be cheaper and easier to store and transport. This means that if they can be the first to successfully launch their products, it will be really bad for us." Mike probably guessed some possibilities in his heart, after all, the problem of masks is getting more and more serious now, Many countries are looking forward to the early development of vaccines, and inevitably, some processes will be accelerated.

"I know all this, Mike, I want a solution." Smith said, knocking on the table.

"It can be carried out in three steps at the same time. The company contacted people from relevant departments in various countries and asked them to strictly review the phase III clinical data of this Chinese biopharmaceutical company. In the approval process, we still have room to operate. In the second step, we can speed up the current progress of some of our company's mrna vaccines, and finally we may be able to market them before them. Finally, the company needs to approve some marketing expenses, and we will Contact some "authoritative" people, as well as media channels, and we can give them some evidence and information. As long as we can convince the public not to trust this vaccine, even if it is on the market, not many people will be willing to take it. It’s still ours.” Mike said seriously.

"Well, yes, then do as you said and explain this matter. I will give you a day to formulate a detailed plan and budget. At that time, I will hold a meeting and invite all relevant departments to join us. Also, take care Investigate the background and resources of this Huaxia Aiying Biological Company." Smith's frown stretched out.

"Understood, boss." Mike nodded and said quickly.

(End of this chapter)